Please login to the form below
monalizumab
This page shows the latest monalizumab news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab
We continue to explore the impact of monalizumab in patients with non-small cell lung cancer across different trials, including the phase 3 PACIFIC-9 trial.”. ... AZ obtained full oncology right to monalizumab in October 2018 by utilising its option
Latest news
-
AstraZeneca to present new oncology data at AACR
and monalizumab, as compared to Imfinzi alone.
-
New data advances AstraZeneca’s “revolution in oncology”
Novel combinations of Imfinzi – with oleclumab, an anti-CD73 monoclonal antibody, and monalizumab, an anti-NKG2A monoclonal antibody – in unresectable, stage 3 NSCLC will also be presented.
-
Innate Pharma and AstraZeneca take monalizumab into phase 3
Innate Pharma’s lead candidate monalizumab – which is licensed by AstraZeneca – is heading for a pivotal phase 3 clinical trial. ... The biotech – based in Marseille, France – will proceed into a phase 3 trial evaluating monalizumab in
-
France’s Innate Pharma eyes $100m Nasdaq IPO
Some of the proceeds will go towards Innate’s lead candidate monalizumab, an anti-NKG2A antibody which was licensed by AstraZeneca last year in a deal that included $100m in ... The French biotech licensed co-commercial rights to the drug at the same
-
AZ invests more in IO with Transgene oncolytic virus deal
It signed a deal with France’s Innate Pharma last October (centred on its anti-NKG2A antibody, monalizumab (IPH2201), and yesterday added an alliance with another French biotech, Transgene.
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
AstraZeneca. Anti-NKG2A antibody (monalizumab), IPH5201 (antibody targeting CD38) and Lumoxiti. #. for hairy cell leukaemia. Development &. commercialisation. collaboration. $307m. ViraTherapeutics/. Boehringer Ingelheim.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Thrive Agency
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
